California State Teachers Retirement System lessened its stake in shares of Opko Health, Inc. (NASDAQ:OPK) by 5.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 608,208 shares of the biotechnology company’s stock after selling 31,749 shares during the period. California State Teachers Retirement System owned approximately 0.11% of Opko Health worth $4,002,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Credit Suisse AG raised its holdings in Opko Health by 122.0% during the 1st quarter. Credit Suisse AG now owns 746,958 shares of the biotechnology company’s stock valued at $5,976,000 after buying an additional 410,445 shares during the period. State Street Corp increased its stake in Opko Health by 40.3% in the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock worth $87,412,000 after purchasing an additional 3,138,685 shares during the period. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD increased its stake in Opko Health by 14.8% in the second quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD now owns 135,401 shares of the biotechnology company’s stock worth $910,000 after purchasing an additional 17,458 shares during the period. State Board of Administration of Florida Retirement System increased its stake in Opko Health by 7.5% in the second quarter. State Board of Administration of Florida Retirement System now owns 400,278 shares of the biotechnology company’s stock worth $2,634,000 after purchasing an additional 27,940 shares during the period. Finally, Vanguard Group Inc. increased its stake in Opko Health by 4.4% in the first quarter. Vanguard Group Inc. now owns 26,322,001 shares of the biotechnology company’s stock worth $210,576,000 after purchasing an additional 1,112,843 shares during the period. Institutional investors own 22.46% of the company’s stock.
In related news, CEO Phillip Md Et Al Frost acquired 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The shares were bought at an average price of $6.05 per share, with a total value of $30,250.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $18,567,153.55. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Opko Health, Inc. acquired 655,738 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The shares were bought at an average cost of $3.05 per share, for a total transaction of $2,000,000.90. Following the transaction, the insider now owns 6,678,752 shares of the company’s stock, valued at $20,370,193.60. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 1,323,038 shares of company stock worth $6,031,060. Insiders own 40.19% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “California State Teachers Retirement System Sells 31,749 Shares of Opko Health, Inc. (OPK)” was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.com-unik.info/2017/11/05/california-state-teachers-retirement-system-sells-31749-shares-of-opko-health-inc-opk.html.
Opko Health, Inc. (NASDAQ:OPK) opened at $6.57 on Friday. The company has a current ratio of 1.67, a quick ratio of 1.50 and a debt-to-equity ratio of 0.02. Opko Health, Inc. has a 52 week low of $5.85 and a 52 week high of $12.15.
Opko Health (NASDAQ:OPK) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. The firm had revenue of $314.20 million for the quarter, compared to analyst estimates of $322.64 million. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The business’s revenue for the quarter was down 12.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.02 earnings per share. equities analysts predict that Opko Health, Inc. will post -0.19 earnings per share for the current year.
A number of research firms have weighed in on OPK. Zacks Investment Research lowered Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Cantor Fitzgerald set a $20.00 target price on Opko Health and gave the stock a “buy” rating in a research note on Thursday, October 12th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $16.00 target price on shares of Opko Health in a research note on Monday, September 25th. BidaskClub upgraded Opko Health from a “sell” rating to a “hold” rating in a research note on Saturday, September 23rd. Finally, J P Morgan Chase & Co lowered Opko Health from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $12.00 to $7.00 in a research note on Thursday, September 14th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Opko Health has an average rating of “Buy” and an average price target of $13.97.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
What are top analysts saying about Opko Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Opko Health Inc. and related companies.